PEGylated Mesoporous Silica Nanoparticles (MCM-41): A Promising Carrier for the Targeted Delivery of Fenbendazole into Prostrate Cancer Cells
Low water solubility and thus low bioavailability limit the clinical application of fenbendazole (FBZ) as a potential anticancer drug. Solubilizing agents, such as Mobil Composition of Matter Number 41 (MCM) as a drug carrier, can improve the water solubility of drugs. In this study, PEGylated MCM (...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/13/10/1605 |
| _version_ | 1797513401606340608 |
|---|---|
| author | Maedeh Koohi Moftakhari Esfahani Seyed Ebrahim Alavi Peter J. Cabot Nazrul Islam Emad L. Izake |
| author_facet | Maedeh Koohi Moftakhari Esfahani Seyed Ebrahim Alavi Peter J. Cabot Nazrul Islam Emad L. Izake |
| author_sort | Maedeh Koohi Moftakhari Esfahani |
| collection | DOAJ |
| description | Low water solubility and thus low bioavailability limit the clinical application of fenbendazole (FBZ) as a potential anticancer drug. Solubilizing agents, such as Mobil Composition of Matter Number 41 (MCM) as a drug carrier, can improve the water solubility of drugs. In this study, PEGylated MCM (PEG-MCM) nanoparticles (NPs) were synthesized and loaded with FBZ (PEG-MCM-FBZ) to improve its solubility and, as a result, its cytotoxicity effect against human prostate cancer PC-3 cells. The loading efficiency of FBZ onto PEG-MCM NPs was 17.2%. The size and zeta potential of PEG-MCM-FBZ NPs were 366.3 ± 6.9 nm and 24.7 ± 0.4 mV, respectively. They had a spherical shape and released the drug in a controlled manner at pH 1.2 and pH 6.2. PEG-MCM-FBZ were found to inhibit the migration of PC-3 cells, increase the cytotoxicity effects of FBZ against PC-3 cells by 3.8-fold, and were more potent by 1.4-fold, when compared to the non-PEGylated NPs. In addition, PEG-MCM-FBZ promoted the production of reactive oxygen species by 1.3- and 1.2-fold, respectively, when compared to FBZ and MCM-FBZ. Overall, the results demonstrate that PEG-MCM-FBZ NPs enhanced FBZ delivery to PC-3 cells; therefore, they have the potential to treat prostate cancer after a comprehensive in vivo study. |
| first_indexed | 2024-03-10T06:16:04Z |
| format | Article |
| id | doaj.art-2f7f1767342446d194ccdbba03ea1d36 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-10T06:16:04Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-2f7f1767342446d194ccdbba03ea1d362023-11-22T19:38:23ZengMDPI AGPharmaceutics1999-49232021-10-011310160510.3390/pharmaceutics13101605PEGylated Mesoporous Silica Nanoparticles (MCM-41): A Promising Carrier for the Targeted Delivery of Fenbendazole into Prostrate Cancer CellsMaedeh Koohi Moftakhari Esfahani0Seyed Ebrahim Alavi1Peter J. Cabot2Nazrul Islam3Emad L. Izake4School of Chemistry and Physics, Science and Engineering Faculty, Queensland University of Technology (QUT), 2 George Street, Brisbane, QLD 4000, AustraliaSchool of Mechanical Engineering, Western Sydney University, Sydney, NSW 2751, AustraliaSchool of Clinical Sciences, Faculty of Health, Queensland University of Technology, 2 George Street, Brisbane, QLD 4000, AustraliaSchool of Pharmacy, The University of Queensland, Woolloongabba, QLD 4102, AustraliaSchool of Chemistry and Physics, Science and Engineering Faculty, Queensland University of Technology (QUT), 2 George Street, Brisbane, QLD 4000, AustraliaLow water solubility and thus low bioavailability limit the clinical application of fenbendazole (FBZ) as a potential anticancer drug. Solubilizing agents, such as Mobil Composition of Matter Number 41 (MCM) as a drug carrier, can improve the water solubility of drugs. In this study, PEGylated MCM (PEG-MCM) nanoparticles (NPs) were synthesized and loaded with FBZ (PEG-MCM-FBZ) to improve its solubility and, as a result, its cytotoxicity effect against human prostate cancer PC-3 cells. The loading efficiency of FBZ onto PEG-MCM NPs was 17.2%. The size and zeta potential of PEG-MCM-FBZ NPs were 366.3 ± 6.9 nm and 24.7 ± 0.4 mV, respectively. They had a spherical shape and released the drug in a controlled manner at pH 1.2 and pH 6.2. PEG-MCM-FBZ were found to inhibit the migration of PC-3 cells, increase the cytotoxicity effects of FBZ against PC-3 cells by 3.8-fold, and were more potent by 1.4-fold, when compared to the non-PEGylated NPs. In addition, PEG-MCM-FBZ promoted the production of reactive oxygen species by 1.3- and 1.2-fold, respectively, when compared to FBZ and MCM-FBZ. Overall, the results demonstrate that PEG-MCM-FBZ NPs enhanced FBZ delivery to PC-3 cells; therefore, they have the potential to treat prostate cancer after a comprehensive in vivo study.https://www.mdpi.com/1999-4923/13/10/1605drug delivery systemsdrug repurposingMCM-41mesoporous silica nanoparticlesolubility |
| spellingShingle | Maedeh Koohi Moftakhari Esfahani Seyed Ebrahim Alavi Peter J. Cabot Nazrul Islam Emad L. Izake PEGylated Mesoporous Silica Nanoparticles (MCM-41): A Promising Carrier for the Targeted Delivery of Fenbendazole into Prostrate Cancer Cells Pharmaceutics drug delivery systems drug repurposing MCM-41 mesoporous silica nanoparticle solubility |
| title | PEGylated Mesoporous Silica Nanoparticles (MCM-41): A Promising Carrier for the Targeted Delivery of Fenbendazole into Prostrate Cancer Cells |
| title_full | PEGylated Mesoporous Silica Nanoparticles (MCM-41): A Promising Carrier for the Targeted Delivery of Fenbendazole into Prostrate Cancer Cells |
| title_fullStr | PEGylated Mesoporous Silica Nanoparticles (MCM-41): A Promising Carrier for the Targeted Delivery of Fenbendazole into Prostrate Cancer Cells |
| title_full_unstemmed | PEGylated Mesoporous Silica Nanoparticles (MCM-41): A Promising Carrier for the Targeted Delivery of Fenbendazole into Prostrate Cancer Cells |
| title_short | PEGylated Mesoporous Silica Nanoparticles (MCM-41): A Promising Carrier for the Targeted Delivery of Fenbendazole into Prostrate Cancer Cells |
| title_sort | pegylated mesoporous silica nanoparticles mcm 41 a promising carrier for the targeted delivery of fenbendazole into prostrate cancer cells |
| topic | drug delivery systems drug repurposing MCM-41 mesoporous silica nanoparticle solubility |
| url | https://www.mdpi.com/1999-4923/13/10/1605 |
| work_keys_str_mv | AT maedehkoohimoftakhariesfahani pegylatedmesoporoussilicananoparticlesmcm41apromisingcarrierforthetargeteddeliveryoffenbendazoleintoprostratecancercells AT seyedebrahimalavi pegylatedmesoporoussilicananoparticlesmcm41apromisingcarrierforthetargeteddeliveryoffenbendazoleintoprostratecancercells AT peterjcabot pegylatedmesoporoussilicananoparticlesmcm41apromisingcarrierforthetargeteddeliveryoffenbendazoleintoprostratecancercells AT nazrulislam pegylatedmesoporoussilicananoparticlesmcm41apromisingcarrierforthetargeteddeliveryoffenbendazoleintoprostratecancercells AT emadlizake pegylatedmesoporoussilicananoparticlesmcm41apromisingcarrierforthetargeteddeliveryoffenbendazoleintoprostratecancercells |